Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan.
Ling-Yi WangHui-Hsia HsiehSung-Chao ChuWei-Chuan ChangYi-Ting KuoTien-Yuan WuPublished in: Therapeutic advances in drug safety (2024)
Oxaliplatin use significantly increased shock risk in stage III CRC patients. Male sex and heart disease are two independent risk factors.